Real-time insights. Smarter decisions. Better trades.
🔍 Search Stocks 14 day Free Trial
CSL LIMITED (CSL)ASX AI Signals has generated 2 signal(s) for CSL during the last 90 days, indicating Moderate trading activity
Latest CSL Signals | |
| 27/05/2026 | BUY |
| 23/04/2026 | SELL |
CSL Share Price | |
| Current Price | $121.810 |
| 52 Week High | $265.402 |
| 52 Week Low: | $92.240 |
| Trading at (% of 52 Week High) | 45.90% |
CSL Limited (ASX: CSL) is a global biotechnology company that develops and delivers innovative medicines and therapies. It specializes in plasma protein biotherapies and influenza vaccines to treat rare and serious diseases. The company operates in multiple countries, serving healthcare needs worldwide.
The Pharmaceuticals, Biotechnology & Life Sciences sector on the ASX includes companies involved in the development, production, and commercialization of drugs, medical devices, and biotechnology products. This sector covers activities such as research and development of new medicines, genetic testing, and innovative healthcare technologies. Companies often work on treatments for diseases, including cancer, infectious diseases, and chronic conditions. The sector plays a crucial role in advancing medical science and improving patient care through innovation.
CSL Limited demonstrates strong market positioning in the biotechnology sector with consistent revenue growth and robust R&D pipeline, supporting a BUY recommendation. However, valuation levels and sector-specific risks moderate the confidence level.
Recommendation follows an Article 20 non-pharmacovigilance procedure Patients currently on TAVNEOS treatment should consult their treating physician
ST. GALLEN, Switzerland, June 26, 2026 /PRNewswire/ -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced today that the European M Recommendation follows an Article 20 non-pharmacovigilance procedure Patients currently on TAVNEOS treatment should consult their treating physician
ST. GALLEN, Switzerland, June 26, 2026 /PRNewswire/ -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced today that the European M CSL Canada is proud to recognize this important milestone of the first Canadian patient to receive HEMGENIX® (etranacogene dezaparvovec), the one-time gene therapy treatment for eligible patients living with hemophilia B, at London Health Sciences Centre in London, Ontario. Following a successful pa This article first appeared on GuruFocus.
CSL Ltd. (CMXHF) suffered its sharpest share-price drop on record after the Australian biotechnology company cut its full-year outlook, warned that its turnaround will take longer than expected, and flagged about $5 billion in additional non-cash, pre-tax i Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Looking at the history of these treLatest CSL LIMITED(CSL) News
CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union
CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union
CSL Canada Announces First Canadian Patient Receives HEMGENIX® (etranacogene dezaparvovec) Hemophilia B Gene Therapy in Ontario, Canada
CSL Plunges 22% After Cutting Outlook And Flagging $5 Billion Impairments
Should Value Investors Buy CSL Limited (CSLLY) Stock?
Get access to daily BUY & SELL signals, advanced AI analysis, watchlists and email alerts.
14 Day Free Trial • Cancel Anytime • Founders Price $15/month
Start My Free Trial